Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab

BACKGROUND: Anti-angiogenic therapy with bevacizumab is the most widely used treatment option for recurrent glioblastoma, but therapeutic response varies substantially and effective biomarkers for patient selection are not available. To this end, we determine whether novel quantitative radiomic stra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Grossmann, Patrick, Narayan, Vivek, Chang, Ken, Rahman, Rifaquat, Abrey, Lauren, Reardon, David A, Schwartz, Lawrence H, Wen, Patrick Y, Alexander, Brian M, Huang, Raymond, Aerts, Hugo J W L
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Neuroimaging
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5716072/
https://ncbi.nlm.nih.gov/pubmed/28499022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox092
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados